[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646921":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":16,"centralContacts":27,"locations":33,"responsibleParty":52,"collaborators":54,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":16,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":16,"enrollmentInfo":67,"targetDuration":16,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":36,"whyStopped":16,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"International Centre for Diarrhoeal Disease Research, Bangladesh","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"A) the intervention arm receiving a single dose","EXPERIMENTAL","dose (\\\u003C5 years old children will receive two doses of OCV at 14 days interval according to the WHO guideline)",[13],"Biological: Cholvax",{"label":15,"type":10,"description":16,"interventionNames":17},"B) the intervention arm receiving two doses at 1-month interval",null,[13],{"label":19,"type":20,"description":16,"interventionNames":16},"C) no intervention or control arm","NO_INTERVENTION",[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":16},"BIOLOGICAL","Cholvax","Produced in Bangladesh and Licenced by the Directorate of Drug Administration (DGDA) for use in Bangladesh",[9,15],[28],{"name":29,"role":30,"phone":31,"phoneExt":16,"email":32},"Dr. Fahima Chowdhury, MBBS, MPH, PhD","CONTACT","+8801730016458","fchowdhury@icddrb.org",[34],{"facility":35,"status":36,"city":37,"state":16,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b)","RECRUITING","Dhaka","1212","Bangladesh","BD",{"type":42,"coordinates":43},"Point",[44,45],90.40744,23.7104,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":50,"phoneExt":16,"email":51},"Dr. Firdausi Qadri, PhD","+8801711595367","fqadri@icddrb.org",{"type":53,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR",[55],{"name":56,"class":6},"Wellcome Sanger Institute","100646921","cholera-control-by-case-area-targeted-interventions-catis-100646921",false,"NCT07685574","Cholera Control by Case-area Targeted Interventions (CATIs)","Case-area Targeted Interventions (CATIs) Among Household Contacts and Neighbouring Households After Defining Cholera Hotspot Areas in Bangladesh: The Effectiveness of OCV and Potential Impact on Cholera Control","Index case eligibility\n\nInclusion Criteria:\n\n1. Some to severe dehydrated diarrheal patient\n2. Provide signed informed consent form\n\nExclusion criteria:\n\n1\\. Resident in a ward already covered by OCV since 2015\n\nVaccination Eligibility\n\nInclusion Criteria:\n\n1. Aged ≥1 year and non-pregnant\n2. Meeting the definition of IHC and NHC\n3. Provide signed informed consent form\n\nExclusion criteria:\n\n1. History of taking OCV\n2. Currently suffering from diarrhea\n3. \\\u003C 1 year of age\n4. Pregnant women (verbally confirmed)\n5. Index case",true,"ALL","1 Year",{"count":68,"type":69},68400,"ESTIMATED","INTERVENTIONAL",[72],"NA","To evaluate the effectiveness of the CATI approach among household contacts in the reduction of cumulative incidence of cholera and explore the genome analysis and immune response of V. cholerae antigen from different hotspots in Dhaka city, cholera cases will be enrolled by rapid diagnostic test (RDT) from the diarrhoeal patients coming to icddr,b Dhaka hospital. Hotspots will be defined as the households (HHs) surrounding the RDT-positive cholera case (around 20-40m radius). The 'Case area targeted interventions' (CATI) will be given by administrating Oral Cholera Vaccine (OCV) with either one dose or two doses of OCV 1 month apart among household contacts (≥1-year age and non-pregnant women) and contacts of the contacts residing in the adjacent HHs. The passive surveillance for cholera will be followed using the icddr,b hospital, and other health facilities. Data on each individual's states of the clusters (e.g., susceptible, exposed, infectious, or recovered) will be tracked throughout the 3 years study follow-up.",[75,76],"Cholera","Methodology Study",[75,78,79,39],"CATI","Cholera Vaccine","2026-07-01",{"date":82,"type":83},"2026-07-06","ACTUAL",{"date":85,"type":83},"2024-09-05",{"date":87,"type":69},"2029-12-31",{"name":5,"class":6},1]